Navigation Links
Dendreon Reports PROVENGE Regulatory and Commercialization Progress and Future Pipeline Plans at Analyst Event
Date:9/24/2009

n a number of malignancies including colon cancer and is targeted for entry into clinical trials in 2012, fulfilling our goal of entering one new ACI into the clinic each year for the next three years.

About PROVENGE

PROVENGE is Dendreon's investigational product candidate for men with advanced prostate cancer and may represent the first in a new class of ACIs specifically designed to engage the patient's own immune system against cancer. PROVENGE and other ACIs are uniquely designed to use live human cells to engage the patient's own immune system with the goal of eliciting a specific long-lasting response against cancer. Dendreon recently announced that the pivotal Phase 3 IMPACT study of PROVENGE in men with advanced prostate cancer met its primary endpoint of improving overall survival compared to a placebo control.

Webcast Replay Information

If you are interested in listening to the replay of the analyst day webcast, you may access it from the Company's website at www.dendreon.com under the "Investor/Webcasts and Presentations" section.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce ACI product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington, and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
2. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
3. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
4. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
5. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
6. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
7. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
8. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
9. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
10. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
11. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 2013 Royal Philips (NYSE: PHG, ... Performance Leader in Imaging Equipment in the 2013 Best ... also received Best in KLAS and Best in Category ... 128 Computed Tomography (CT), Ingenia 1.5T and 3.0T ... The annual Best in KLAS Awards: Medical Imaging & ...
(Date:6/18/2013)... June 18, 2013  Specialty Coating Systems ... in Parylene coating technologies: SCS microRESIST™ Antimicrobial ... of Parylene with antimicrobial properties to effectively ... components. (Logo: http://photos.prnewswire.com/prnh/20130618/DE33772LOGO ... increase and continue to pose a challenge ...
(Date:6/18/2013)... -- Decision Resources, one of the world,s leading research and ... the past 12 months, 25 percent of surveyed physicians from ... , Italy , Spain ... have been required to change the antiretroviral (ARV) prescription for ... costs. Additionally, more than 40 percent of respondents report that ...
Breaking Medicine Technology:Philips Named 2013 Overall Performance Leader In Imaging Equipment By KLAS 2Specialty Coating Systems Announces New Antimicrobial Parylene Technology 2One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs 2One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs 3
... Nov. 7, 2011 Zimmer Holdings, Inc. ... agreed to sell $550 million of senior notes in an ... Smith Incorporated, BNP Paribas Securities Corp. and RBS Securities ... LLC, Credit Suisse Securities (USA) LLC, Citigroup Global Markets ...
... 7, 2011 ERT (Nasdaq: ERT ), ... President and CEO is scheduled to present at the ... on Nov. 15, 2011 in Las Vegas. ... Company,s corporate website at http://www.ert.com . The webcast ...
Cached Medicine Technology:Zimmer Holdings, Inc. Agrees to Sell $550 Million of Senior Notes 2ERT to Present at the Citi 2011 Global Health Care Conference on November 15, 2011 2
(Date:6/18/2013)... Medical Center clinical researchers have launched an innovative ... evaluate the ability of a patient,s own stem ... peripheral arterial disease (PAD). , Led by ... University Hospitals Case Medical Center,s Harrington Heart & ... Western Reserve University School of Medicine, the clinical ...
(Date:6/18/2013)... Belleville, Ill. (PRWEB) June 18, 2013 More ... older are living with HIV/AIDS, according to the Centers for ... don’t know they are infected. In support of National HIV ... Social Security Disability Insurance (SSDI) representation, the CDC ... HIV testing. , The CDC reports about 50,000 new ...
(Date:6/18/2013)... 2013 myCNAjobs announces the addition of ... articles, and tips to the Caregiver Resources Center. , ... the 10,000+ retiring baby boomers each day, the need ... job resources has never been greater. myCNAjobs, ... community, recently launched the first-ever free resource center for ...
(Date:6/18/2013)... 18, 2013 A new $119 million ... burgeoning aquaculture industry is redefining the way consumers get ... most acclaimed personal culinary chefs on the Emerald Coast ... of sustainable seafood and the promising industry of aquaculture. ... days. Many consumers strive to fully partake in the ...
(Date:6/18/2013)... Pomona, Calif. (PRWEB) June 18, 2013 ... associate professor of Family Medicine for the College of ... of Health Sciences has been elected president of the ... Gov. Edmund G. Brown Jr. appointed Connett, a 1984 ... , OMBC members recently elected Connett to the position ...
Breaking Medicine News(10 mins):Health News:UH Case Medical Center launches novel clinical trial using stem cells to prevent amputation 2Health News:Allsup Observes National HIV Testing Day June 27 2Health News:Allsup Observes National HIV Testing Day June 27 3Health News:myCNAjobs Adds New Resources to Growing Caregiver Career Center 2Health News:New $119 Million Industry Swimming Up the East Coast 2
... likely to be infected with Hepatitis C virus compared ... get treatment for their liver disease because current antiviral ... this epidemiological background, the article by Schaefer and colleagues, ... important study in the field, write Sanjeev Arora and ...
... 72 posters, lectures, and mini-symposia given by University of Pennsylvania ... new research findings on the molecular workings of several types ... American Society of Cell Biology takes place on December 1-5, ... Huntington,s Disease: A new role has been discovered for ...
... 3 inVentiv Health, Inc.,(Nasdaq: VTIV ) today ... be held Tuesday, December 11th, 2007 in New York ... 9:00 a.m. as announced earlier, and,will conclude at noon, ... business overview, presentations by the,leaders of each of the ...
... N.C., Dec. 3 LipoScience, Inc. is pleased to,announce ... of Directors., Mr. Landon has over 30 years ... retiring from active management, Mr. Landon,was Vice President & ... full functional responsibility for all of DuPont,s Medical,Products businesses, ...
... research from a lab at Florida State University reveals ... it, resisting temptations to misbehave, our fuel tank is ... , Florida State psychologist Roy F. Baumeister and his ... M. Tice, Florida State, showed this with an experiment ...
... An inhaled immune system stimulant protects mice against ... and fungal infections of the lungs, a research ... Texas M. D. Anderson Cancer Center reports at ... have implications for protecting immuno-compromised patients against infection ...
Cached Medicine News:Health News:Treating patients with psychiatric disorders for hepatitis C 2Health News:Penn talks at ASCB touch on cancer, neurodegenerative diseases, and MD 2Health News:inVentiv Health Provides Updated Information on December 11th Investor Day 2Health News:inVentiv Health Provides Updated Information on December 11th Investor Day 3Health News:Got sugar? Glucose affects our ability to resist temptation 2Health News:Aerosol launches immune response in lungs to wipe out lethal infections 2Health News:Aerosol launches immune response in lungs to wipe out lethal infections 3
... ,Offers an average 5:1 increase in usage time ... of a standard cannula. , ,The combination ... ambulatory oxygen patients a superior alternative to liquid ... warranty. , ,NOTE: ...
Redesigning the World's Oxygen Therapy One Device at a Time. , ,Everything you like about our OXYMATIC 400 Series conservers, only better!...
... Accutrol is similar in design to the ... incorporates a temperature probe at the tip ... can accurately determine the patient's core body ... accuracy comparable to a pulmonary artery catheter ...
... Ultra Micro Shafts For Insertion Through A ... Light-Weight ... Shafts For A More Comfortable Approach., ,Recessed ... Cap Supplied For Protection Of Jaws During ...
Medicine Products: